Lisa Kays

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16

Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models

Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul et al. · Molecular Cancer Therapeutics · 2014 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 85 citations · Full text

Medicine, Oncology, Pharmacology +17

Keeping the Promise: Five Benefits of Girls' Secondary Education

Rihani Ma, Lisa Kays, Stephanie Psaki · 2006 · 75 citations

Public Affairs, Education Policy, Secondary Education +14

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul et al. · PLoS ONE · 2016 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17